Eur J Cancer: The effect of DNA damage repair status on the activity of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer

Previous studies have shown that Cabazitaxel can improve the overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC) after treatment failure with abiraterone/enzalutamide and docetaxel, although The benefits of the presence of DNA damage repair (DDR) defects are unclear

This study aims to clarify the effect of DNA damage repair status on the efficacy of cabazitaxel in the treatment of mCRPC patients

This is a prospective multicenter study that recruited mCRPC patients treated with cabazitaxel who underwent DDR tumor tissue analysis

Prognosis analysis of patients grouped by DDR status according to tissue analysis

Among the 190 patients with organized sequencing data (95 DDR+, 95 DDR-), the proportions of patients in the DDR+ and DDR- groups who obtained PSA50 after cabazitaxel treatment were 32% (29/92) and 36%, respectively (33/92; p=0.

Prognostic analysis of patients grouped by liquid biopsy DDR status

Similar results were observed in the liquid biopsy cohort (DDR+, n=63)

In summary, the results of the study show that the existence of DNS damage repair defects does not affect the effect of cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer , but cabazitaxel is used in patients who have previously received PARPi treatment.

Aldea Mihaela,Lam Laurent,Orillard Emeline et al.